Search Results
Apr 21, 2026, 08:00 ET Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
ZYMFENTRA.NEUROLOGIC REACTIONSAgents that inhibit TNF have been associated with central nervous system (CNS) manifestation of systemic vasculitis, seizure and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders,
More news about: Celltrion
Apr 21, 2026, 08:00 ET Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Apr 20, 2026, 16:23 ET Psilera Commends Landmark Executive Order Prioritizing Psychedelic Therapies
Oppenheimer CNS Focus EventCo-Founder & CEO Chris Witowski, PhD, speaking on panel.6/22 - 6/25
More news about: Psilera
Apr 20, 2026, 08:55 ET NYSE Content Update: SEC Chair Paul Atkins to Ring Opening Bell at NYSE
Chair Paul Atkins is at the NYSE this morning to celebrate the one-year anniversary of being sworn into the role.Cohen & Steers (NYSE: CNS) executive Jeffrey Palma will join Taking Stock this afternoon to discuss the significance of the company's 40th anniversary.Fireblocks
More news about: New York Stock Exchange
Apr 20, 2026, 02:30 ET New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
otherwise not have ready access to such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can be found
More news about: Specialised Therapeutics
Apr 17, 2026, 16:31 ET SK Life Science Labs to Present New Preclinical Data on Targeted Protein Degradation at AACR Annual Meeting 2026
Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, today announced the presentation of three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place
More news about: SK Life Science Labs
Apr 17, 2026, 16:01 ET New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Apr 17, 2026, 15:00 ET Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026
melanoma following failure of standard therapyResponses observed across multiple RAS/MAPK-driven tumors with early evidence of CNS activityApproximately 8,000 NRAS and BRAF Class II/III melanoma patients diagnosed each year in the U.S. with no approved
More news about: Nested Therapeutics Inc.
Apr 17, 2026, 10:39 ET Bracco Receives Health Canada Approval for VUEWAY® injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging
visualize lesions with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity in:the Central Nervous System (CNS), including brain, spine and surrounding tissuesthe Body, including head and neck, thorax (including breast), abdomen (including liver and kidneys),
More news about: Bracco Group
Apr 17, 2026, 09:00 ET Parker Institute for Cancer Immunotherapy Network Shapes the Future Of Immunotherapy with Latest Research at AACR Annual Meeting 2026
Abstract 3714)Pediatric & CNS CancersRobbie Majzner, MD (DFCI): Ganglioside targeting for neuroblastoma (
More news about: Parker Institute for Cancer Immunotherapy
Apr 16, 2026, 16:18 ET Cohen & Steers Reports Results for First Quarter 2026
NEW YORK, April 16, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended March 31, 2026. The earnings release along with the accompanying earnings presentation can be viewed
More news about: Cohen & Steers, Inc.
Apr 16, 2026, 09:00 ET NEURELIS TO PRESENT ANALYSES OF IMMEDIATE-USE SEIZURE TREATMENT AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Apr 16, 2026, 08:04 ET SK Life Science, Inc. Launches Epilepsy Connect to Empower Advanced Practice Providers in Epilepsy Care
pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with 12 compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content
More news about: SK Life Science, Inc.
Apr 16, 2026, 08:00 ET Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting
to design highly selective compounds with optimal CNS exposure. Brenig's pipeline includes BT-267, a LRRK2 inhibitor in clinical development for Parkinson's disease, and BT-409, an NLRP3 inhibitor targeting neuroinflammatory pathways across multiple CNS indications and obesity.Forward-Looking
More news about: Brenig Therapeutics
Apr 15, 2026, 15:00 ET Perceptive Discovery Announces Strategic Partnership with MH3D and Launch of α-Sight™ to Advance Alpha Radiopharmaceutical Imaging
DiscoveryPerceptive Discovery is a scientific partner to the global biopharmaceutical industry, providing integrated preclinical solutions across oncology, CNS, and radiopharmaceutical development. The company combines expertise in imaging, radiochemistry, and quantitative analysis to deliver high-quality, decision-ready
More news about: Perceptive Discovery
Apr 15, 2026, 09:10 ET Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Bioworks (NASDAQ: LNAI) is an AI-driven biotechnology company focused on accelerating drug discovery and development across central nervous system (CNS) and other high unmet need areas. Lunai integrates data analytics and experimental biology to improve development efficiency, reduce cost, and increase
More news about: Lunai Bioworks Inc.
Apr 15, 2026, 08:00 ET LG CNS Unveils Logistics Robot Operating at -15°F, Steps Up North American Expansion
of Smart Logistics & City Business Division at LG CNS. "We will continue to drive our global business expansion by leveraging our distinctive strengths in high-density, high-efficiency logistics operations."About LG CNSLG CNS is a leading Korean AX (AI Transformation) company that
More news about: LG CNS
Apr 15, 2026, 08:00 ET CRC's Chief Scientific Officer, Gary Kay, Ph.D., to Speak at 2026 Lifesavers Conference on Roadway Safety
developers work to ensure patient safety while maintaining the scientific standards required to support therapeutic development."CRC's work in CNS clinical trials frequently includes the evaluation of cognitive and functional outcomes, including the effects of investigational and approved therapies
More news about: Cognitive Research Corporation
Apr 14, 2026, 10:17 ET CSF Liquid Biopsy May Help Clarify Inconclusive Leptomeningeal Disease Cases, Study Finds
treatment response over time.Key FindingsThe study analyzed 118 CSF specimens from patients with a provisional diagnosis of metastatic CNS cancer, spanning breast, lung, and other primary malignancies. Summit™ identified clinically significant variants in all 118 specimens across 22 of the
More news about: Belay Diagnostics
Apr 14, 2026, 09:00 ET Cohen & Steers Announces U.S. Wealth Leadership Appointments
NEW YORK, April 14, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced a series of leadership appointments and organizational enhancements designed to strengthen its U.S. wealth distribution capabilities
More news about: Cohen & Steers, Inc.
Apr 14, 2026, 09:00 ET RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Apr 14, 2026, 08:32 ET Spirographic AI LLC Launches Tissue-Specific Polypharmacology Platform Demonstrating Industry-Leading Drug Target Prediction Accuracy
has direct applications across the pharmaceutical development pipeline:Early safety screening — Cardiac (hERG, NaV1.5), CNS, and organ-specific toxicity prediction before synthesisDrug repurposing — Novel target identification across existing compound librariesRegulatory
More news about: Spirographic AI, LLC
Apr 14, 2026, 07:30 ET Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleinopathies and other CNS diseases.Among CNS unmet conditions, brain metastasis (BM) remains a lethal progression of the primary cancer in urgent need of novel and effective therapies.
More news about: Galmed Pharmaceuticals Ltd.
Apr 14, 2026, 03:00 ET ARTHEx Biotech Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.The Company headquarters are in Valencia, Spain.For more information on ArthemiR™, please visit
More news about: ARTHEx Biotech
Apr 13, 2026, 08:01 ET Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update
years of industry and academic experience. He most recently held senior roles at Takeda, including Head of CNS Early Development and Head of Translational Biomarkers/Imaging, and previously led early CNS clinical development at Eli Lilly. He holds an M.D. from the University of Vienna and completed specialty
More news about: Leal Therapeutics